<DOC>
	<DOC>NCT00539396</DOC>
	<brief_summary>A 3 month, randomized, open label, multi-center study of Technosphere/Insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine</brief_summary>
	<brief_title>A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes currently receiving SC insulin at mealtimes for at least 3 months BMI &lt;40 kg/m squared HbA1c greater than or equal to 7% and less than or equal to 11.5% Serum creatinine less than 2 for males and less than 1.8 for females Acceptable pulmonary function Significant hepatic disease Previously diagnosed pulmonary disease, ketoacidosis of evidence of severe secondary complications of diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>